Jinwon Life Sciences Obtains Approval for Subsidiary VGXI's New Factory Occupancy

[Asia Economy Reporter Jang Hyowon] Genwin Life Sciences announced on the 21st that its subsidiary VGXI, a plasmid DNA contract development and manufacturing organization (CDMO), has received occupancy approval after the completion inspection of a new factory built in Deison Technology Park, Conroe City, Texas, USA.

The company explained, "The inspection was conducted according to Conroe's strict safety diagnosis and fire inspection procedures for facilities, and with the acquisition of occupancy approval, we will move in as soon as possible to commence commercial production of high-quality plasmid DNA."

Park Younggeun, CEO of Genwin Life Sciences, stated, "The new factory is a large-scale plasmid DNA production facility with differentiated quality that can meet the demand for DNA and RNA pharmaceuticals based on VGXI's accumulated expertise. It is also capable of producing mRNA bulk, establishing itself as an advanced facility that can satisfy the diverse needs of our clients."